chemotherapy
-
Astrazeneca Withdraws Regulatory Submissions for Cancer Drug
AstraZeneca has withdrawn the regulatory submissions for the use of Zactima (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), from the US Food and Drug Administration (FDA) and the Europ…
chemotherapy | 12 November 2009
-
Iressa Provides Greater Efficacy in NSCLC Treatment Compared to Chemotherapy
Data from the Phase III first line Iressa Pan-Asia Study (IPASS), has demonstrated Progression-Free Survival (PFS: the length of time a patient lives without their tumour growing) for the oral anti-cancer drug Iressa, compared with intravenous carbop…
chemotherapy | 27 August 2009
-
Invida to Market Antiemetic Patch in Asia Pacific
Invida Pharmaceutical Holdings, a specialty pharmaceutical company based in Singapore has signed an exclusive license and supply agreement for Sancuso. The product is a patent-protected transdermal patch for the prevention of chemotherapy-induced…
chemotherapy | 12 February 2009
-
New generation chemotherapy uses magnetic nanoparticles
A partnership between Siemens Corporate Technology and the University Hospital of Erlangen in Germany has paved the way for more precise and effective treatment of non-operable tumors through the use of anti-cancer drugs transported by magnetic parti…
chemotherapy | 27 November 2008
-
First Patient In A US Phase 1 Study Of Hematide To Treat Chemotherapy Induced Anemia Dosed
Takeda Pharmaceutical Company Limited and Affymax, Inc. said Takeda has dosed the first patient in the US in a clinical trial of the investigational new drug, Hematide, for the treatment of anemia in cancer patients undergoing chemotherapy. Under …
chemotherapy | 29 January 2008
